Skip to main content
Premium Trial:

Request an Annual Quote

US Genomics, Northrop Grumman to Develop, Sell Pathogen-Detection Tool for US Gov't

NEW YORK (GenomeWeb News) — US Genomics today said it will work with aerospace and defense giant Northrop Grumman to develop and market US Genomics’ biodetection technology for the Department of Homeland Security.
 
US Genomics has already received around $23 million in funding from the Homeland Security to develop a prototype of the instrument, which uses the company’s single molecule-detection technology to find “a wide range of pathogens and toxins.”
 
US Genomics said its mapping technology uses a universal reagent set to produce a “genomic signature” for each DNA sample, allowing for identification of pathogens.
 
The company said the test is sensitive enough to present “extremely low” rates of false positives. The platform does not use pathogen-specific reagents and needs no amplification, the company said.
 
The test would also enable researchers to detect species that were modified or were designed to avoid detection, US Genomics said.
 
US Genomics CEO John Canepa said the Northrop Grumman partnership is “the next logical step in moving our technology from the laboratory toward providing real protection from biological attacks.”

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.